Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 14/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.61 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930829 | 0.81 | CDK2 (0.57) | CDK2CHEK1CCNA2CCNA1MAPKAPK2 | |
| SCHEMBL11930830 | 0.81 | CDK2 (0.57) | CDK2CHEK1CCNA2CCNA1MAPKAPK2 | |
| SCHEMBL14543068 | 0.81 | CDK2 (0.57) | CDK2CHEK1CCNA2CCNA1MAPKAPK2 | |
| SCHEMBL11930803 | 0.81 | CHEK1 (0.41) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL11930815 | 0.79 | CDK2 (0.47) | CDK2CHEK1CCNA2CCNA1MAPKAPK2 | |
| SCHEMBL11930806 | 0.77 | TYK2 (0.44) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL11930867 | 0.76 | CHEK1 (1.00) | CDK2CHEK1CCNA2CCNA1GSK3B | |
| SCHEMBL11930870 | 0.74 | CHEK1 (0.73) | CDK2CHEK1CCNA2CCNA1GSK3B | |
| SCHEMBL12952900 | 0.74 | GSK3B (0.71) | CDK2GSK3B | |
| SCHEMBL12952850 | 0.74 | GSK3B (0.71) | CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CDK2 64/4885CHEK1 8/4885CCNA2 1270/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | CDK2 64/4885CHEK1 8/4885CCNA2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.